Cantor Fitzgerald Positive Sequenom

Cantor Fitzgerald thinks Sequenom SQNMis on-track with steady progress of its MDx pipeline. Cantor thinks Sequenom is positioned for rapid buildout of its platform from proprietary and in-licensed MDxs. Cantor Fitzgerald thinks SQNM offers the security of a revenue stream from genome analysis with the upside of molecular diagnostics which could be a substantial opportunity. Cantor reiterates its BUY rating on Sequenom.